Promyelocytic leukemia retinoic acid receptor alpha fusion protein (PML-RARA)

The Promyelocytic leukemia retinoic acid receptor alpha fusion protein (PML-RARA) results from the balanced chromosomal translocation t(15;17)(q24;q21), fusing the PML and RARA genes. This fusion protein acts as a master driver of acute promyelocytic leukemia by repressing genes essential for myeloid differentiation and altering nuclear architecture, blocking maturation at the promyelocyte stage and promoting survival and proliferation of leukemic cells. PML-RARA disrupts normal retinoic acid signaling and recruits co-repressors and chromatin-modifying proteins, inducing repressive chromatin at key loci. The fusion protein is specifically targeted by therapies such as all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), allowing therapeutic reversal of the differentiation block and restoring the characteristic nuclear bodies. Monitoring the presence and clearance of PML-RARA is central to diagnosis, treatment, and assessment of minimal residual disease in APL patients.

Other names

PML-RARAPML::RARAPML/RARAPromyelocytic leukemia-retinoic acid receptor alpha fusion protein

ATRA binds to PML-RARA, alters co-repressor interactions, enables differentiation of leukemic cells\nATO promotes degradation of PML-RARA, restoring normal nuclear body architecture and triggering apoptosis